Phase 2 N=84 Multimodality Intervention for Function and Metabolism in SCI
Spinal Cord Injuries
Primary: Change From Baseline in VO2 Peak (L/Min) Achieved During Arm Ergometry Exercise Alone — 0.11; 0.09 L/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.
Chronic Kidney Disease · Inflammation · Cardiovascular Risk
Primary: Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) Levels From Baseline (Average of All Hs-CRP Values Prior to the Administration of Study Drug) to the End…
Phase 2 N=70 Altering Lipids for Tolerance of Aromatase Inhibitor Therapy
Breast Cancer
Primary: Change in Percentage of Total Fatty Acids for Each Polyunsaturated Fatty Acid (PUFA) Group From Start of Omega-3 Fatty Acid (O3-FA) Supplementation to 3 Months of O3-FA…
Phase 2 N=39 Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
Head and Neck Cancer
Primary: Percentage of Patients With Grade 3 and 4 Adverse Events of Nivolumab — 17 Participants
Phase 2 N=10 Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
Head and Neck Cancer
Primary: Overall Response — 0; 1; 1; 8 Participants
Phase 2 N=25 DPX-Survivac and Checkpoint Inhibitor in DLBCL
Adult Diffuse Large Cell Lymphoma · Recurrent · Adult Refractory Diffuse Large B-Cell Lymphoma
Primary: Objective Response Rate Using Modified Cheson Criteria to Treatment With DPX-Survivac and Low Dose Cyclophosphamide Administered Together With Pembrolizumab in…
Phase 2 N=69 PDC-1421 Treatment in Adult Patients With ADHD
Attention-Deficit Hyperactivity Disorder (ADHD)
Primary: Number of Participants With Improvement ≥ 40% in ADHD-RS-IV From Baseline up to 8 Weeks Treatment — 11; 9; 10 Participants
Phase 2 N=176 Video-assisted Thoracoscopic Surgery - Exparel Study
Pain, Postoperative
Primary: Number of Subjects With Post-operative Opioid Usage — 42; 58 Participants
Phase 2 N=45 SLM + Axitinib for Clear Cell RCC
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Primary: Incidence of Adverse Events (AE) Per CTCAE 4.03 — 3; 5; 7; 20 Participants
Phase 2 N=89 A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Percentages of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI 75) Score at Week 16 — 4.2; 41.9…
Phase 2 N=150 SMART Use of Medication for the Treatment of Adolescent Severe Obesity
Adolescent Obesity
Primary: Percent Change in Body Mass Index (BMI) — -9.62; -12.27; -4.53; -2.53 % change in body mass index (BMI)
Phase 2 N=211 Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
Borderline Personality Disorder
Primary: Efficacy: Difference in the CGI-S A/A From Baseline to Average of Weeks 8 to 12 — -1.47; -1.31 Scores on a scale — p=0.2266
Phase 2 N=123 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of Head and Neck
Primary: Percentage of Participants With Confirmed Objective Response, as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST…
Phase 2 N=315 Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
Cytomegalovirus Infection
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 33; 59; 40; 12 Participants
Phase 2 N=345 Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria
Malaria
Primary: Primary Safety Endpoint - The Number of Adverse Events Occurring After Investigational Product (IP) Administration — 6; 5; 8; 3 participants